Five things for pharma marketers to know: Monday, January 22, 2018

Share this content:


1. To expand its portfolio in hemophilia and other rare blood disorders, Sanofi said it will acquire Bioverativ for $11.6 billion. Bioverativ markets long-acting treatments Eloctate and Alprolix, which could replace factor replacement therapies as standard of care. (NYT)

2. As part of a push to expand its oncology portfolio, Celgene said it will acquire Juno Therapeutics for $9 billion. Juno is developing experimental blood cancer therapy JCAR017. (WSJ)

3. Teva Pharmaceutical Industries will lay off more than 200 staff in three of its Philadelphia-area locations, including its North American headquarters in North Wales, Penn. (Philly)

4. Delaware filed a lawsuit against Purdue Pharma, Endo Pharmaceuticals, CVS Health, and others for disseminating misleading marketing materials that contributed to the opioid crisis. (Reuters)

5. The Department of Health and Human Services initiated a contingency staffing plan that will keep Medicare, the Centers for Medicare and Medicaid Services, and other operations running during the federal government shutdown. (Health Data Management)

Share this content:
Scroll down to see the next article